Skip to main content

Table 2 Relationship between therapeutic outcomes and thyroid-absorbed dose calculated from each method

From: Investigation of post-therapeutic image-based thyroid dosimetry using quantitative SPECT/CT, iodine biokinetics, and the MIRD’s voxel S values in Graves’ disease

 HypothyroidismEuthyroidismHyperthyroidism
Cases32 (67%)12 (25%)4 (8%)
DEANM [Gy]a231.4 ± 55.9 (136.3–344.6)223.6 ± 68.5 (104.3–362.3)241.0 ± 24.7 (214.6–267.5)
\( {\overline{D}}_{\mathrm{image}} \) [Gy]b137.5 ± 29.7 (85.4–200.7)117.2 ± 39.5 (53.1–186.2)139.3 ± 12.4 (126.0–155.9)
\( {\overline{D}}_{\mathrm{image},\mathrm{PVC}} \) [Gy]c224.3 ± 60.0 (119.3–348.6)199.4 ± 67.9 (95.7–323.0)222.1 ± 10.2 (211.6–235.8)
  1. *Data are expressed as mean ± 1 standard deviation (SD), if appropriate, as maximum and minimum values
  2. aHypo- vs Eu-, p = 0.785; Eu- vs Hyper-, p = 0.379; Hypo- vs Hyper-, p = 0.645
  3. bHypo- vs Eu-, p = 0.063; Eu- vs Hyper-, p = 0.133; Hypo- vs Hyper-, p = 0.981
  4. cHypo- vs Eu-, p = 0.234; Eu- vs Hyper-, p = 0.317; Hypo- vs Hyper-, p = 0.903
  5. (Bonferroni-corrected Wilcoxon-Mann-Whitney test)